SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-016480
Filing Date
2023-05-12
Accepted
2023-05-12 06:03:33
Documents
53
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 690153
2 ex31-1.htm EX-31.1 19477
3 ex31-2.htm EX-31.2 17729
4 ex32-1.htm EX-32.1 10645
  Complete submission text file 0001493152-23-016480.txt   3886331

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20230331.xsd EX-101.SCH 30307
6 XBRL CALCULATION FILE zvsa-20230331_cal.xml EX-101.CAL 39870
7 XBRL DEFINITION FILE zvsa-20230331_def.xml EX-101.DEF 176130
8 XBRL LABEL FILE zvsa-20230331_lab.xml EX-101.LAB 254382
9 XBRL PRESENTATION FILE zvsa-20230331_pre.xml EX-101.PRE 222124
47 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 499027
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41184 | Film No.: 23913017
SIC: 2834 Pharmaceutical Preparations